Company Overview
Aces Diagnostics was founded with a simple goal: to give physicians better tools to diagnose Lyme disease earlier and more accurately.
Driven by both scientific expertise and personal experience, our team includes leaders in Lyme disease research, diagnostics, bioinformatics, regulatory affairs, and commercialization. Together, we are working to address one of the most persistent challenges in medicine—accurate Lyme disease diagnosis.
Our flagship technology, LYMESEEK™, has demonstrated greater than 90% accuracy across all stages of Lyme disease and is designed to help clinicians identify infection sooner than current testing approaches.
We believe earlier answers lead to earlier treatment, better outcomes, and fewer patients left searching for a diagnosis.
Our Personal Story
Aces Diagnostics was born from a shared experience no parent should have to face.
After watching their daughters struggle for years with debilitating symptoms caused by Lyme disease, our founders experienced firsthand the consequences of delayed and inaccurate diagnosis. What began as a search for answers became a mission to improve the future for Lyme disease patients everywhere.
Founded in 2024, after 9 years of research, Aces Diagnostics is committed to developing innovative diagnostic solutions that help physicians identify Lyme disease earlier, enabling faster treatment and better outcomes for patients.
Team
Dedication. Expertise. Passion.
The team behind LymeSeek combines expertise in diagnostics, Lyme disease research, regulatory strategy, commercialization, and artificial intelligence. Together, our leadership team has decades of experience bringing innovative healthcare technologies from development through market adoption.
.png)
.png)
Scientific & Strategic Advisors
Our advisors bring expertise spanning infectious disease, diagnostics, commercialization, reimbursement, and healthcare innovation.
.jpg)
.jpg)
